Arhan, M. Et Al. 2018. COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN'S DISEASE FOR TURKEY. VALUE IN HEALTH , vol.21 .

Arhan, M., Tezel, H. A., TÖRÜNER, M., Bilaloglu, B., Koral, S., & Ozer, E., (2018). COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN'S DISEASE FOR TURKEY. VALUE IN HEALTH , vol.21.

Arhan, M. Et Al. "COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN'S DISEASE FOR TURKEY," VALUE IN HEALTH , vol.21, 2018

Arhan, M. Et Al. "COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN'S DISEASE FOR TURKEY." VALUE IN HEALTH , vol.21, 2018

Arhan, M. Et Al. (2018) . "COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN'S DISEASE FOR TURKEY." VALUE IN HEALTH , vol.21.

@article{article, author={M. Arhan Et Al. }, title={COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN'S DISEASE FOR TURKEY}, journal={VALUE IN HEALTH}, year=2018}